A Randomized, Double-blinded Trial of Single Ascending Doses of ZP4207 Administered s.c. or i.m. to HV and a SD of ZP4207 Administered s.c. to Hypoglycemic T1D to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207 as Compared to an Active Comparator

Trial Profile

A Randomized, Double-blinded Trial of Single Ascending Doses of ZP4207 Administered s.c. or i.m. to HV and a SD of ZP4207 Administered s.c. to Hypoglycemic T1D to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207 as Compared to an Active Comparator

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Dasiglucagon (Primary) ; Glucagon
  • Indications Hypoglycaemia
  • Focus Adverse reactions; First in man
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 14 Jul 2015 Planned End Date changed from 1 May 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
    • 26 Jun 2015 Results published in the Zealand Pharma Media Release.
    • 22 May 2015 Status changed from recruiting to completed as per Zealand Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top